Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 253 results found. Search for [ BioNTech ]

Results 80 to 100 of 253
BusinessToday.In
November 18, 2020
Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report


BusinessToday.In
November 18, 2020
Pfizer and BioNTech informed that primary efficacy analysis of their coronavirus vaccine candidate showed that it was 95 per cent effective beginning 28 days after the first dose


Dipak Mondal
November 18, 2020
Why are other bidders in the race to acquire DHFL (either its retail business or the combined business) not amused with Adani Group's bid for the housing finance company?


Niti Kiran
November 18, 2020
Markets currently are witnessing strong flows from foreign portfolio investors (FPIs) with investments already surpassing the October levels


Manoj Sharma
November 18, 2020
Pfizer says Phase 3 study of their COVID-19 vaccine candidate met \"all primary efficacy endpoints\".  During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy


BusinessToday.In
November 18, 2020
The FDA requires manufacturers to follow at least half of the people who received vaccines in their Phase 3 clinical trials for two months, to ensure there is at least that amount of safety data before a vaccine is considered for use


Manali
November 18, 2020
Defining the four attributes, Serum Institute of India CEO Adar Poonawalla posted that a good vaccine must be safe, should offer long-term protection against targeted disease, can be transported and stored at a manageable temperature, and lastly, affordable


Reuters
November 18, 2020
The Sinovac findings, published in a peer-reviewed paper in medical journal The Lancet Infectious Diseases, came from results in Phase I and Phase II clinical trials in China involving more than 700 participants


BusinessToday.In
November 17, 2020
These early efficacy figures don't tell the whole story. The data results are based on a relatively smaller group of participants who received these vaccine shots. The actual efficacy could be known only after the final results are out as Phase 3 clinical trials end


BusinessToday.In
November 17, 2020
Pfizer filed a possible patent infringement petition against both companies in the United States District Court for the District of Delaware and two counts last week


BusinessToday.In
November 17, 2020
Moderna had announced on November 16 that after Phase 3 of trials their COVID-19 vaccine candidate was 94.5% effective in preventing coronavirus infection


Manoj Sharma
November 17, 2020
Dr Ali Nouri, molecular biologist and President, Federation of American Scientists, has explained how these vaccine candidates work in simplest possible way on Twitter


Reuters
November 17, 2020
Interim data from a late-stage trial indicated Moderna's vaccine was 94.5% effective in preventing COVID-19


BusinessToday.In
November 17, 2020
Moderna had announced on November 16 that after Phase 3 of trials their COVID-19 vaccine candidate was 94.5% effective in preventing coronavirus infection


BusinessToday.In
November 17, 2020
Moderna had announced on November 16 that after Phase 3 of trials their COVID-19 vaccine candidate was 94.5% effective in preventing coronavirus infection


Aseem Thapliyal
November 17, 2020
Nifty too hit a record high in early trade with the index risingabove 12,900 for the first time ever


BusinessToday.In
November 17, 2020
The early results provide strong signals that the coronavirus vaccine could prevent a majority of disease when large groups of people are vaccinated. However, the actual efficacy could be known only after the final results are out once the stage 3 trials end


Reuters
November 17, 2020
The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate after getting the green signal from the Drugs Controller General of India


BusinessToday.In
November 17, 2020
Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report


BusinessToday.In
November 16, 2020
Moderna stated that its COVID-19 vaccine candidate remains stable for 30 days at 2-degree Celsius to 8-degree Celsius, the temperature of a standard home or medical refrigerator


PAGES 5 OF 13  12345